GP KFPs / SAQs · addiction-medicine
Opioid dependence treatment - KFP-style written assessment
KFP-style staged scenarios on opioid dependence treatment: choosing between methadone and buprenorphine-naloxone, the mortality evidence, safe induction, cessation risk, take-home naloxone, and the GP prescribing role.
On this page
Study tools
Target exams
RACGP KFPMRCGP
Prompt
Opioid dependence treatment - KFP-style written assessment
KFP 1 (10 marks)
A 32-year-old man with heroin dependence wants to start treatment. He has been using daily for four years, injecting intravenously. He wants to know which medication is better. [1]
- What are the first-line pharmacotherapy options and how do they compare? (4) [1]
- What does the evidence show about mortality during treatment? (3) [1] [2]
- What safety precautions apply during methadone induction? (3) [1] [2]
Model answers
- Methadone and buprenorphine-naloxone are both first-line. Meta-analysis shows equivalent retention rates between them (no significant difference in RCTs), though buprenorphine's partial mu-agonism provides a ceiling effect on respiratory depression making it safer in overdose. Methadone may retain some severe-dependence patients better. [1]
- All-cause mortality during OAT is less than half that during time out of treatment (RR 0.47). Pooled mortality rates: 11.3 per 1000 PY during methadone vs 36.1 out; 4.3 vs 9.5 for buprenorphine. Suicide, drug-related, alcohol-related, cardiovascular and cancer mortality are all reduced during OAT. [1] [2]
- Methadone induction carries almost double the all-cause mortality risk in the first four weeks. Start low (10-20 mg), titrate slowly, monitor closely. Buprenorphine requires mild-to-moderate withdrawal before first dose to avoid precipitated withdrawal. [1] [2]
References5ShowHide
- [1]Santo T Jr, Clark B, Hickman M et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA psychiatry, 2021.PMID 34076676
- [2]Sordo L, Barrio G, Bravo MJ et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical research ed.), 2017.PMID 28446428
- [4]Malta M, Varatharajan T, Russell C et al. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. PLoS medicine, 2019.PMID 31891578
- [5]Miller L Bridging Emergency and Prevention: A Systematic Review of Take-Home Naloxone Programs. Journal of addictions nursing, 2025.PMID 40846320
- [6]Fraeyman J, Symons L, Van Royen P et al. How to overcome hurdles in opiate substitution treatment? A qualitative study with general practitioners in Belgium. The European journal of general practice, 2016.PMID 26799738